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ABSTRACT
Melanoma is an aggressive cancer with highly metastatic ability. We propose 
cofilin-1, a key protein in the regulation of actin dynamics and migration, as a 
prognostic marker. We determined cofilin-1 levels in a retrospective cohort of patients 
with melanomas and benign lesions of melanocytes (nevi) by immunohistochemistry. 
Higher cofilin-1 levels were found in malignant melanoma (MM) with Breslow Index 
(BI)>2 vs MM with BI<2, melanoma in situ (MIS) and nevi and also in MM with 
metastasis vs MM without detected metastasis. Kaplan-Meier survival curves were 
performed, clustering patients according to either the type of melanocytic lesions 
or cofilin-1 level. Survival curves demonstrated worse prognosis of patients with 
high vs low cofilin-1 levels. TCGA database analysis of melanoma also showed low 
survival in patients with upregulated cofilin-1 mRNA vs patients without alteration in 
CFL1 mRNA expression. As cofilin-1 has a dual function depending on its intracellular 
localization, we evaluated nuclear and cytoplasmic levels of cofilin-1 in melanoma and 
nevi samples by immunofluorescence. MM with high Breslow index and metastatic 
cells not only presented cytoplasmic cofilin-1, but also showed this protein at the 
nucleus. An increase in nuclear/cytoplasmic cofilin-1 mean fluorescence ratio was 
observed in MM with BI>2 vs MM with BI<2, MIS and nevi.
In conclusion, an association of cofilin-1 levels with malignant features and an 
inverse correlation with survival were demonstrated. Moreover, this study suggests 
that not only the higher levels of cofilin-1, but also its nuclear localization can be 
proposed as marker of worse outcome of patients with melanoma.
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INTRODUCTION
Malignant melanoma (MM) is one of the most 
aggressive cancers, with high metastatic ability and 
increasing mortality rates. Although melanoma accounts 
for less than 1% of skin cancer, it is responsible for almost 
90% of skin cancer deaths. It is estimated that 91,270 
new cases of invasive melanoma will be diagnosed in the 
U.S. in 2018 [1]. The staging system most often used for 
melanoma is the American Joint Commission on Cancer 
(AJCC) TNM system [2]. Early stage melanoma can be 
cured by surgery alone, but late stage metastatic disease 
has limited treatment options. Although new approaches 
that include immunotherapy and targeted therapies have 
led to improvements in patient outcomes [3–6], the 
advanced disease has still extremely poor outcomes with 
5 year overall survival of less than 10% [7]. There is a 
highly significant decline in survival rates as melanoma 
thickness (also called Breslow index, BI) increase. 
Besides, the chances of relapse do not differ much 
between stage T2 and stage T3 patients; in addition, for 
very early stage melanoma (≤1 mm, T1a or T1b) the risk 
of recurrence ranges between 1% and 12% [8].
Conventional tissue biomarkers, such as BI, 
ulceration, mitotic rate and lymph node positivity, remain 
the backbone prognostic indicators in melanoma [9]. 
However, since recurrence rate is largely independent from 
stages defined by morphological and morphometric criteria, 
there is a strong need for identification of additional robust 
prognostic factors to support decision-making processes 
[8]. In this context, several immunohistochemical (IHC) 
markers are used in the clinical setting for the evaluation 
of melanocytic lesions (e.g. S100, HMB45, Melan-A/
MART1 and MITF). While these markers are useful 
in differentiating melanocytic from nonmelanocytic 
neoplasms, they are not capable of reliably distinguishing 
neither benign from malignant melanocytic neoplasms 
nor primary from advanced/metastatic melanoma [10]. In 
addition, BRAF mutations occur commonly in both nevi 
and melanomas [11]. Thus, additional molecular markers 
of these cutaneous lesions are needed in order to accurately 
predict the behavior of melanoma in individual patients to 
monitor disease progression, recurrence, and response to 
treatment [12–14].
The ability of cells to migrate and invade the 
dermis is critical in metastatic melanoma and therefore 
an indicator of poor prognosis. Thus, proteins involved in 
transforming melanoma cells into a migratory phenotype 
can be proposed as prognostic markers. In this sense, high 
levels of cofilin-1, which favors migration by inducing 
cycles of actin polymerization/depolymerization [15], 
has been found in metastatic cells [16, 17]. In addition, 
cofilin-1 as an effector of transforming growth factor-β 
is an important contributor of epithelial mesenchymal 
transition programming, which confers invasive and 
metastatic properties during cancer progression [18]. In 
this regard, cofilin-1 overexpression was associated with 
increased migration in colon adenocarcinoma cells [19] 
and has been used as poor prognosis marker, related to 
metastasis, in non-small cell lung cancer patients [20, 21] 
and invasive breast cancer cells [17]. Besides, a previous 
work from our laboratory demonstrated in a melanoma 
model with different degree of malignancy a correlation 
among the high levels of cofilin-1 and the migratory, 
invasive and metastatic ability of cells [22], suggesting its 
relevance in melanoma progression.
The activities of different proteins can be controlled 
by their concentration and subcellular localization. 
Cofilin-1 is enriched in cytoplasmic locations as 
regulator of actin-cytoskeleton and cell locomotion [23]. 
However, cofilin-1 also has a bipartite nuclear localization 
signal (NLS) [24], which allows its involvement in 
transcriptional elongation and nuclear morphology and 
function, including chromosome regulation. Cofilin-1 also 
translocates actin, which lacks of a NLS, into the nucleus, 
where actin regulates transcription and gene activation 
[25]. However, the nuclear localization of cofilin-1 was 
not described in melanoma progression.
These evidences lead us to determine the levels and 
subcellular localization of cofilin-1 in melanoma human 
samples with different degrees of malignancy, in order to 
define this protein as predictor of advanced melanoma. 
In this sense, we demonstrated increased cofilin-1 levels 
associated with malignant features of melanoma, such as 
BI and metastasis. We also found an inverse correlation 
between cofilin-1 levels and patient survival. Remarkably, 
cofilin-1 was also observed in the nucleus of more 
malignant melanomas. These results allow us to propose 
cofilin-1 as a prognostic marker of melanoma.
RESULTS
Cofilin-1 protein levels and patients overall 
survival
The clinicopathological features of patients and 
cofilin-1 immunocontent, expressed as percentage of 
samples with low or high cofilin-1 for each condition, 
are summarized in Table 1. Results show a significant 
association between high levels of cofilin-1 and MM 
advanced stages (p<0.001), metastasis (p<0.01), 
increased number of mitosis per field (p<0.05) and BI 
(p<0.05).
Increased cofilin-1 immunocontent was detected 
by IHC in MM vs MIS and nevi (Figure 1A). The 
quantification of cofilin-1 immunocontent as O.D. mean 
values confirmed its significant increase in cofilin-1 for 
MM vs nevi and MIS, and for MM BI>2 vs all types 
of lesions (Figure 1B). The O.D. values of cofilin-1 per 
sample were distributed within a range of variation, 
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Table 1: Epidemiological and clinical features of the cohort of patients with benign and malignant melanocytic 
lesions according to cofilin-1 immunocontent
Characteristics Cofilin-1 Immunocontent
Low (< 0.08 A.U.) High (> 0.08 A.U.)
Cohort, n=42 57.1 % 42.9 %
Age, years 58.6 ± 21.3 69.6 ± 16.6
Sex
 Men, n=22 59.1 % 40.9 %
 Women, n=18 50 % 50 %
 Undetermined, n=2 100 % 0 %
Histological Type
 Nevus, n=9 100 % 0 %
 MIS, n=8 87.5 % 12.5 %
 MM
  SSM, n=5 80 % 20 %
  LMM, n=1 0 % 100 %
  NMM, n=10 30 % 70 %
  Undetermined MM, n=9 11.1 % 88.9 %
Tumor Stage (TNM)
 0, n=8 87.5 % 12.5 %
 IA, n=4 50 % 50 %
 IB, n=4 50 % 50 %
 IIB, n=1 100 % 0 %
 III, n=2 50 % 50 %
 IV, n=9 22.2 % 77.8 %
 Undetermined, n=5 0 % 100 %
Metastasis
 No, n=17 70.6 % 29.4 %
 Yes, n=11 18.2 % 81.8 %
Mitosis/Field
 < 1, n=10 60 % 40 %
 1-5, n=13 15.4 % 84.6 %
 > 5, n=1 0 % 100 %
Breslow Index
 < 2 mm, n=10 50 % 50 %
 > 2 mm, n=15 20 % 80 %
Metastasis includes lymph nodes and distant metastases. Abbreviations: LMM, Lentigo maligna melanoma; MIS, 
Melanoma in situ; MM, Malignant melanoma; SSM, Superficial spreading melanoma; NMM, Nodular malignant 
melanoma.
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between 0.009, the lowest value attributed to a nevus, and 
0.13, the highest value obtained from a MM BI>2.
Kaplan-Meier survival curves of patients clustered 
according to the type of lesions: nevus, MIS, MM BI<2 
and MM BI>2, and to the cofilin-1 immunocontent 
were performed. Survival analysis of patients with these 
different types of melanocytic lesions revealed significant 
differences (p < 0.05) among curves evaluated by log-
rank test for trend (Figure 2A). Regarding cofilin-1 
immunocontent, survival curves indicated that those 
patients who have higher cofilin-1 levels present lower 
survival rate at 5 years (p<0.0001) analyzed by both log-
rank test and Gehan-Breslow-Wilcoxon test (Figure 2B). 
Moreover, a significant negative correlation between 
survival percentage and cofilin-1 immunocontent 
(Spearman Correlation: R=-0.73, p=0) was found (Figure 
2C). Therefore, the levels of cofilin-1 can be associated 
with the melanoma outcome in this patient cohort.
Cofilin-1 mRNA expression and patients overall 
survival from TCGA melanoma data set
Regarding the association of cofilin-1 levels 
and BI, a significant increased expression of CFL1 
mRNA was observed in MM BI>2 compared with MM 
BI<2 (p<0.05) in the melanoma cohort from the TCGA 
Research Network (Figure 3A). Overall patient survival 
status analysis showed 59.3 % of deceased patients with 
melanomas where CFL1 expression was up-regulated 
vs 47 % of deceased patients with melanomas where 
CFL1 was no altered (Figure 3B). Kaplan-Meier survival 
curves analysis indicated that those who have higher 
CFL1 mRNA expression levels present lower survival 
rate (p<0.001) analyzed by both log-rank test and Gehan-
Breslow-Wilcoxon test (Figure 3C). Remarkably, these 
results support those obtained in our cohort of patients, 
suggesting that not only at protein level but also at mRNA 
expression level, cofilin-1 can be associated with a worse 
prognosis in melanoma.
Subcellular localization of cofilin-1 in malignant 
vs benign melanocytic lesions
Melanoma cells with different degree of 
malignancy exhibited differential subcellular localization 
of cofilin-1 detected by immunocytofluorescence (Figure 
4A). Cofilin-1 was found localized both in cytoplasm 
and nucleus in metastatic A375-G10 cells, while it was 
mainly observed in cytoplasm in non-metastatic A375 
cells. A significant difference on the ratio of nuclear/
Figure 1: Cofilin-1 immmunocontent in benign and malignant melanocytic lesions. (A) Representative IHC images in tissue 
sections of benign and malignant melanocytic lesions (microphotograph obtained with a 1000X magnification; bar represents 50 μm), normal 
skin (negative control, microphotograph obtained with a 40X magnification) and experimental breast cancer (positive control, microphotograph 
obtained with a 400X magnification). (B) O.D. mean values expressed as arbitrary units (A.U.) of cofilin-1 immunocontent in tissue sections. 
Data are expressed as mean ± SD. *p < 0.05 MM BI<2 vs nevus and MIS; *p < 0.05 MM BI>2 vs MM BI<2; p < 0.001 MM BI<2 vs normal 
skin; ***p < 0.001 MM BI>2 vs normal skin, nevus and MIS; ###p<0.001 breast cancer vs normal skin; #p<0.05 breast cancer vs nevus and MIS.
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cytoplasmic cofilin-1 mean fluorescence was found 
between these metastatic and non-metastatic melanoma 
cells (Figure 4B).
Regarding cofilin-1 detection by immunohisto-
fluorescence in benign and malignant melanocytic lesions, 
representative images of the immunofluorescence nuclear/
cytoplasm values of each type of lesion, quantified as 
described in Materials and Methods section, are shown 
in Figure 4C. The ratio of nuclear/cytoplasmic cofilin-1 
mean fluorescence exhibited significant differences 
between MM and MIS vs nevi. MM with BI>2 showed the 
higher ratio as compared with MIS and MM BI<2 (Figure 
4D). Thus, more aggressive melanomas also exhibited 
increased nuclear levels of cofilin-1.
DISCUSSION
Proteins involved in the induction of cell migration 
and invasion may be relevant as potential molecular 
markers of aggressiveness and bad prognosis. Particularly, 
Figure 2: Kaplan–Meier survival curves of patients clustered according to the type of melanocytic lesions and to the 
cofilin-1 immunocontent. (A) Overall survival in 5 years of patients clustered according to the type of lesions: nevus, MIS, MM 
BI<2 and MM BI>2. (B) In order to evaluate the cofilin-1 performance to discriminate between good and bad prognosis, patients were 
clustered according cofilin-1 immunocontent in low and high cofilin-1 with a cutoff of 0.08 A.U. of O.D. mean values and Kaplan-Meier 
survival curves were performed. (C) Correlation between survival percentage and cofilin-1 immunocontent. Data represent mean ± SD 
of survival percentage and cofilin-1 immunocontent. A significant correlation between both parameters resulted from the Spearman’s 
regression analysis (R=-0.73, p=0).
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we focused on cofilin-1, which is a key mediator of actin 
cytoskeleton polymerization and migration [26]. This 
is the first study in a cohort of patients with melanoma 
that correlates cofilin-1 levels with malignant features 
and survival. Molecular biomarkers are needed to 
optimize melanoma treatment due to their potential role 
in early diagnosis, prognosis and predictive response to 
therapies. The currently available melanoma biomarkers 
are mainly based on histopathological parameters. 
Breslow thickness has been demonstrated as one of the 
main clinicopathological parameters for predicting the 
outcome of patients with melanoma local lesions, which 
concomitant with mitotic index and lymph nodes allows 
defining melanoma staging [27]. However, there remains 
variability in prognosis among melanomas classified in the 
same stage, for example for stage IIA melanomas, the risk 
of relapse and mortality may approach 25%. This current 
criteria lack the ability to identify the individuals who 
Figure 3: Cofilin-1 mRNA (CFL1) expression, BI and overall patient survival analyzed from TCGA melanoma data 
set. (A) Tukey boxplot of CFL1 mRNA expression z-scores (RNA Seq V2 RSEM) vs BI clustered as MM BI<2 and MM BI>2. Mean is 
show as +. *p < 0.05 MM BI>2 vs MM BI<2. (B) Overall survival status of patients with melanomas where CFL1 mRNA was up-regulated 
or no altered. (C) Kaplan–Meier survival curves of patients with melanomas where CFL1 mRNA was up-regulated or no altered.
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will progress in each staging group [28, 29]. Therefore, 
during the last years the emphasis has turned to the study 
of molecular markers to achieve a better interpretation 
of endogenous mechanisms of melanoma and a more 
accurately prognosis, which could have implications in 
personalized therapies [30].
In this sense, we demonstrated an association 
between cofilin-1 levels and malignancy, measured by 
Breslow thickness, melanoma staging, mitotic index 
and presence of metastasis, in melanoma patients. This 
is in agreement with an in vitro previous study, where 
we reported high levels of cofilin-1 in migrating cells 
with metastatic ability compared with non-migratory 
neither metastatic control cells in an experimental model 
of human melanoma [22]. Besides, proteomic studies 
showed differential expression of cofilin-1 isoforms in two 
melanoma cell lines compared with a melanocyte cell line 
[31] and increased expression of cofilin-1 in metastatic 
lymph node compared with matched human primary 
cutaneous melanoma tissue of the same patients [32]. 
Furthermore, the analysis of cofilin-1 mRNA levels in 
the melanoma cohort from the TCGA Research Network 
supported the results obtained in our cohort of patients.
Moreover, we demonstrated an inverse correlation 
between cofilin-1 and survival, both at protein and 
mRNA expression levels in melanoma. The association of 
cofilin-1 with the outcome of patients was also described 
in other types of tumors, i.e. lung, breast and ovarian 
carcinoma [20, 21, 33, 34].
Regarding cofilin-1 intracellular localization, we 
demonstrated not only the increase of total levels of this 
protein, but also its higher expression in the nucleus of 
metastatic melanoma cells and MM with BI>2. Thus, 
besides the well-known function of cofilin-1 in migration 
when it is located at cytoplasm, we propose that cofilin-1 
would be controlling other malignant features at the 
nucleus in melanoma. This could be mediated by actin 
efficient shuttling into the nucleus through its interaction 
with cofilin-1’s NLS [24]. In addition, cofilin-1 is part 
of the RNA polymerase II transcriptional machinery 
with a role in transcriptional elongation [35]. Consistent 
with our results, recent evidence showed an association 
Figure 4: Cofilin-1 showed both cytoplasmic and nuclear localization in more aggressive melanomas. (A) Representative 
immunocytofluorescence images of cofilin-1 with their corresponding nuclear staining using DAPI detection in non-metastatic 
A375 vs metastatic A375-G10 human melanoma cells. Bar represents 50 μm. (B) Quantification of cofilin-1 cytoplasmic and nuclear 
expression in A375 and A375-G10 cells showed as the ratio of nuclear/cytoplasmic mean fluorescence values. Data represent mean ± 
SD. *p < 0.05 A375-G10 vs A375. (C) Representative images of cofilin-1 and HMB-45 (as a marker of melanocyte lineage), detected 
by immunohistofluorescence in tissue sections of benign and malignant melanocytic lesions of patients with their nuclear staining using 
DAPI detection. Bar represents 50 μm. (D) Quantification of cofilin-1 cytoplasmic and nuclear expression in tissue sections of benign and 
malignant melanocytic lesions showed as the ratio of nuclear/cytoplasmic mean fluorescence values. Data represent mean ± SD. **p < 0.01 
MIS vs nevus; ***p < 0.001 MM BI<2 vs nevus; ***p < 0.001 MM BI>2 vs MM BI<2, MIS and nevus.
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between the nuclear localization of cofilin-1 and bladder 
cancer progression [36]. Furthermore, a partial nuclear 
translocation of phosphorylated/inactive cofilin-1 was 
observed in colon adenocarcinoma cell lines characterized 
by an invasive phenotype [37].
In conclusion, our results are an important step 
toward the validation process of cofilin-1 as a prognostic 
biomarker in melanoma. We suggest that cofilin-1 could 
be included in a molecular profile signature for melanoma 
prognosis based on genes or proteins involved in control 
of invasion and metastasis. Thus, further in-depth 
investigations related to cofilin-1 pathway in melanoma 
would be relevant to define potential biomarker signatures 
for earlier prognosis and development of new targeted 
therapies.
MATERIALS AND METHODS
Patient cohort and clinicopathological diagnosis
Formalin-fixed paraffin-embedded benign and 
malignant melanocytic lesions from patients diagnosed 
between 2000 and 2008 were obtained from the 
Pathological Anatomy Service, Hospital Italiano de 
Buenos Aires, Argentina (HIBA). The cohort consisted of 
42 patients. The average age of the patients was 62.5 ± 20 
years. Regarding sex, 52.4% of the patients were men and 
42.8% were women. No significant differences in age and 
percentage of sex were found between groups of patients 
with the different diagnoses. The pathological diagnoses 
were reviewed and classified by two independent 
pathologists, according to World Health Organization 
criteria. Information such as histological type, melanoma 
stage, Breslow index (BI) and patient outcome were 
collected. Inclusion criteria were nevus, melanoma in situ 
(MIS), primary and metastatic melanoma previously 
diagnosed and with clinical follow-up of at least 5 years 
available. Besides, mitotic index was quantified as number 
of mitosis in 10 high power (400X magnification) fields as 
a measure of the growth rate.
This work has been carried out in accordance with 
The Code of Ethics of the World Medical Association 
(Declaration of Helsinki) for experiments involving 
human samples. The research program, including studies 
on archival and stored materials, was approved by the 
Research Protocols Ethics Committee of the HIBA 
(#1922).
The STROBE (Strengthening the Reporting of 
Observational Studies in Epidemiology) guidelines were 
used to ensure the reporting of this observational study 
(see Supplementary Information) [38, 39].
Detection of cofilin-1 by immunohistochemistry
Tissue sections were deparaffinized with xylene and 
rehydrated through a series of graded alcohols. To detect 
cofilin-1, antigen retrieval was performed by incubating 
with proteinase K 40 μg/mL in TE buffer (Tris 50 mM, 
EDTA 1 mM and Triton X100 0.5%, pH 8) for 1 h at 37ºC. 
Endogenous peroxidases were blocked with 5% hydrogen 
peroxide in methanol and to avoid nonspecific background 
staining, slides were incubated for 1 h with 1% bovine 
serum albumin (BSA) (Sigma) in phosphate-buffer saline 
(PBS). Rabbit polyclonal anti-cofilin-1 antibody 1:100 
(Abcam, ab42824) was used. The immunogen sequence 
used by Abcam for obtaining ab42824 anti-cofilin 
antibody is a 14 amino acid peptide at the C-terminus 
of the human cofilin-1 protein. Samples were incubated 
with this antibody diluted 1:100, overnight at 4°C. After 
incubation, Super Sensitive IHC Detection Systems 
(BioGenex) kit, based on horseradish peroxidase-labeled 
polymer conjugated, was used following manufacturer’s 
instructions. After staining with diaminobenzidine 
solution, sections were dehydrated with alcohol, cleared 
in xylene and mounted (Entellan, Merck). In all cases, 
negative controls were obtained omitting the primary 
antibody, representing the background staining value in 
optical density (O.D.) measurements. Tissue sections 
obtained from normal skin and from breast cancer were 
used as negative and positive control tissues [17, 21], 
respectively.
The intensity of cofilin-1 IHC reaction was 
quantitatively measured in images obtained with an 
Olympus BX51 microscope coupled to a CCD camera 
(Olympus DP70). Five images were captured for each 
case on the same day by a single observer. Images were 
quantified as previously described [21], using Image J 
software (National Institutes of Health, Bethesda, USA) 
[40]. Results were expressed as the O.D. mean values in 
arbitrary units (A.U.).
TCGA melanoma data set analysis
Data from 479 melanoma samples of a cohort of 
471 patients generated by the TCGA Research Network 
(http://cancergenome.nih.gov/) [41, 42] was used for 
supplementary analysis of cofilin-1 at mRNA level 
(CFL1). Information regarding melanoma samples and 
CFL1, such as BI, overall patient survival status and 
mRNA expression z-scores (RNA Seq V2 RSEM), was 
obtained. Data about MM BI were clustered in MM BI<2 
and MM BI>2.
Survival data analysis
Standard Kaplan-Meier survival curves analyses 
were performed.
The survival curves were compared using the log-
rank and Gehan-Breslow-Wilcoxon tests, and patients were 
clustered according to either the type of melanocytic lesions 
or cofilin-1 IHC expression level. Clustering of benign 
and malignant lesions include: nevi, MIS, MM BI<2 and 
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MM BI>2. Regarding cofilin-1 immunocontent a cutoff of 
0.08 A.U. of O.D. mean values was considered to cluster 
IHC samples between low and high cofilin-1 levels. This 
value was selected taking into account that the higher level 
of cofilin-1 expression of benign lesions was lower than 
0.08. For TCGA data set, survival curves were performed 
in the same way, but CFL1 was divided in up-regulated or 
no altered according with a z-score threshold ± 2 and the 
time of the overall patient survival status was presented in 
months.
Detection and subcellular localization of cofilin-1 
by immunofluorescence
The intracellular localization of cofilin-1 was 
evaluated in a cellular model of melanoma developed 
in our laboratory [22] and in tissue sections of benign 
and malignant melanocytic lesions from patients. 
Immunocytofluorescence assay of cofilin-1 in non-
metastatic A375 and metastatic A375-G10 cells 
was performed as previously described [22]. For 
immunohistofluorescence in patient samples, tissue sections 
were deparaffinized and rehydrated as described above. 
Microwave antigen retrieval was performed by placing 
the slides in 10 mM citrate buffer (pH 6.0) for 10 min. 
Tissue sections were blocked with 1% BSA in PBS and 
incubated overnight at 4°C with a rabbit polyclonal anti-
cofilin-1 antibody 1:100 (Abcam, ab42824), then washed 
with PBS pH 8.2 and incubated with secondary fluorescein 
isothiocyanate (FITC)-conjugated anti-rabbit IgG (Sigma) 
for 1 h in the dark at room temperature. In order to evaluate 
cofilin-1 staining only in melanocytic lineage cells in the 
tissue sections of patients, after a second block with 1% 
BSA in PBS, samples were incubated overnight at 4°C 
with a mouse monoclonal HMB-45 antibody 1:400 (Cell 
Marque), then the samples were washed with PBS pH 8.2 
and incubated with secondary rhodamine-conjugated anti-
mouse IgG (Sigma) for 1 h in the dark at room temperature. 
Samples were washed, counterstained and mounted with 1 
μg/mL 4’,6-diamidine-2’-phenylindole (DAPI, Sigma) and 
PBS/glycerol (80:20) in the dark. Cells were examined in 
an Olympus BX51 epifluorescence microscope utilizing 
immersion oil with a 100 (UPlanApo 100 X/1.35 oil) 
objective lens. For each sample of tissue sections from 
patients, FITC, rhodamine and DAPI images were serially 
captured by a CCD camera (Olympus DP70) at least five 
images were captured for each case on the same day by 
a single observer. FITC and DAPI images were captured 
in the same way for samples of melanoma cell model. 
In all cases negative controls were obtained omitting the 
primary antibody. A code number was given to each image. 
Random sampling methods were used to select the images 
to evaluate mean fluorescence of cofilin-1 in cytoplasms 
and nuclei. The original DAPI and cofilin-1 color images 
were merged for the selection of nuclei and cytoplasms. 
All cells from each selected images from non-metastatic 
A375 and metastatic A375-G10 cells and all the positive 
cells for melanocytic lineage staining in each selected image 
from tissue sections of patients were measured. To quantify 
mean fluorescence intensity for cofilin-1, Image J software 
(National Institutes of Health, Bethesda, USA) [40] was 
used. All images were converted to 8-bit grayscale, the 
background level was subtracted and the staining intensities 
were determined on the 0–255 greyscale. Random areas of 
equal size in each cytoplasm and nucleus were delimited 
in order to obtain the mean grey value, which represents 
mean fluorescence. An average of 1000 cells was evaluated 
per sample type. The relative nuclear/cytoplasmic value of 
mean fluorescence was calculated for each cell, both in the 
cell model of melanoma and in tissue sections from patients.
Statistical analysis
Data are presented as mean ± SD. Significant changes 
were assessed using one-way analysis of variance and 
nonparametric Kruskal-Wallis test followed by Tukey’s or 
Dunn’s multiple comparison tests, respectively, to determine 
significant differences between group means. For cell 
experiments analysis, nonparametric t test was performed. 
P-values of less than 0.05 were considered significant for all 
tests. Regression analysis was performed when appropriate.
Abbreviations
AJCC, American Joint Commission on Cancer; 
A.U., arbitrary units; BI, Breslow Index; BSA, bovine 
serum albumin; DAPI, 4’,6-diamidine-2’-phenylindole; 
FITC, fluorescein isothiocyanate; HIBA, Hospital 
Italiano de Buenos Aires; IHC, immunohystochemistry; 
MIS, melanoma in situ; MM, malignant melanoma; NLS, 
nuclear localization signal; O.D., optical density; PBS, 
phosphate-buffer saline; STROBE, Strengthening the 
Reporting of Observational Studies in Epidemiology; 
TCGA, The Cancer Genome Atlas; TE, Tris-EDTA; TNM, 
tumor, lymph nodes and metastasis.
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